Svae
Tor-Einar Svae, Modling AT
Patent application number | Description | Published |
---|---|---|
20110104298 | Universally applicable virus inactivated blood plasma produced from portions of non-Caucasians plasma - A blood plasma for human use pooled from donors which belong to 10% or more to a non-Caucasian population, the plasma obtainable by mixing blood or blood plasma of blood groups A and B, optionally AB without admixing substantial amounts of blood or blood plasma of blood group 0 characterized in that | 05-05-2011 |
Tor-Einar Svae, Hurdal NO
Patent application number | Description | Published |
---|---|---|
20090092678 | Universally applicable blood plasma - A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. | 04-09-2009 |
20110008459 | Universally applicable blood plasma - A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0. | 01-13-2011 |
Tor-Einar Svae, Moedling AT
Patent application number | Description | Published |
---|---|---|
20100159023 | METHOD FOR STABILISING BLOOD PLASMA COMPONENTS IN A LYOPHILISATE - Process for the stabilization of blood plasma components in a lyophilizate, wherein | 06-24-2010 |
Tor-Einar Svae, Vienna AT
Patent application number | Description | Published |
---|---|---|
20150250879 | TEST FOR HEMOLYTIC POTENTIAL OF PHARMACEUTICAL PRODUCTS AND FORMULATIONS FOR RISK MINIMIZATION - A non-hemolytic acidic composition comprising an immunoglobulin selected from immunoglobulin A, immunoglobulin G or immunoglobulin M at a pH value in the range of 4.65 to 5.7 comprising one or more excipients selected from amino acids, sugars and sugar alcohols in a concentration range of 100-350 mmol/l, in particular 200-350 mmol/l, characterized in that it displays an optical density (OD) in the range of 0.14 to −0.1 when the OD is determined in a spectrophotometer at 414 nm at a film thickness of 0.825 mm; and its use in an assay for determination of the hemolytic potential of intravenously applied pharmaceuticals and compositions and preparations displaying a reduced potential of hemolysis when being applied intravenously. | 09-10-2015 |